Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia
| Autor: | Yoshihiko Shimizu, Eriko Kawate, Yasuhito Kobayashi, Naho Kagiyama, Miyuki Ueda, Takashi Nishida, Kenji Takano, Yotaro Takaku, Yasuhiro Morimoto, Tsutomu Yanagisawa, Ryota Ozawa, Keisuke Kasuga, Yoichi Kobayashi, Taisuke Isono, Naomi Takata, Takashi Ishiguro, Kazuyoshi Kurashima, Noboru Takayanagi, Chiaki Hosoda |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Wuhan medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Case Report Novel coronavirus 2019 03 medical and health sciences 0302 clinical medicine Internal medicine BALF bronchoalveolar lavage fluid medicine SARS-CoV severe acute respiratory syndrome coronavirus 2 Respiratory system COVID-19 coronavirus disease 2019 lcsh:RC705-779 business.industry SARS-CoV-2 cHCoV conventional human coronavirus Clinical course COVID-19 Lopinavir lcsh:Diseases of the respiratory system Pneumonia medicine.disease respiratory tract diseases BVBs bronchovascular bundles CT computed tomography GGOs ground-glass opacities 030228 respiratory system Respiratory failure 030220 oncology & carcinogenesis HFNC high-flow nasal cannula CRP C-reactive protein Ritonavir business medicine.drug |
| Zdroj: | Respiratory Medicine Case Reports Respiratory Medicine Case Reports, Vol 31, Iss, Pp 101207-(2020) |
| ISSN: | 2213-0071 |
| Popis: | Objective To clarify what future problems must be resolved and how clinical findings of SARS-CoV-2 infection differ from those of cHCoV infection. Methods Patients and Methods Clinical characteristics of 14 patients with laboratory-confirmed Coronavirus disease 2019 (COVID-19) and 5 patients with cHCoV pneumonia admitted to our institution and treated up to March 8, 2020, were retrospectively analyzed. Results On admission, 10 patients had pneumonia, 5 of whom had pulmonary shadows detectable only via computed tomography (CT). During hospitalization, another patient with no pulmonary shadows on admission developed pneumonia. In total, 11 (78.6%) of the 14 patients developed pneumonia, indicating its high prevalence in COVID-19. During hospitalization, the patients' symptoms spontaneously relapsed and resolved, and gastrointestinal symptoms were frequently found. C-reactive protein values showed correlation with the patients’ clinical courses. Ritonavir/lopinavir were administered to 5 patients whose respiratory conditions worsened during admission, all of whom improved. However, the pneumonia in the 6 other patients improved without antivirals. None of the 14 patients died, whereas 5 other patients with cHCoV pneumonia were in respiratory failure on admission, and one patient (20%) died. Conclusion Both SARS-CoV-2 and cHCoV can cause severe pneumonia. Problems for future resolution include whether antiviral agents administered in cases of mild or moderate severity can reduce the number of severe cases, and whether antivirals administered in severe cases can reduce mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|